* Has resubmitted to U.S. FDA NDA for its investigational candidate Yosprala Source text for Eikon: Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223…
The post BRIEF-Aralez Pharmaceuticals says resubmitted to NDA for Yosprala appeared first on NASDAQ.